Cardiovascular pharmacology of CPU-23

A novel calcium channel blocker

Hui Dong, Gareth J. Waldron, William C. Cole, Christopher Triggle

Research output: Contribution to journalArticle

Abstract

The results of our studies conducted at the molecular, cellular, tissue, organ, and whole animals levels suggest that CPU-23 is a novel calcium channel blocker. This is further confirmed by recent studies utilizing the path-clamp technique, in which CPU-23 (1-10 μM) dose-dependently blocked inward Ca2+ currents via L-type Ca2+ channels in single smooth muscle cells isolated from the rat tail artery. Although derived from tetrandrine, CPU-23 interacts at distinct binding sites on L-type calcium channels and exerts a more potent biological action than tetrandrine. These data suggest that CPU-23, because of its novel and unique chemical structure, may be a useful tool for the study of L-type calcium channels. The obvious antihypertensive and antiarrhythmic actions of CPU-23 and its respiratory effects indicate that CPU-23 may be a useful therapeutic agent worthy of further study and development. One weakness of CPU-23 is that its potency and selectivity for the vasculature is less than those of dihydropyridine derivatives, but this may be improved by a better understanding of the structure-activity relationship of tetrahydroisoquinolines and their interaction at L-type calcium channels. This could be accomplished, for instance, by further studies of the effects of substituted tetrahydroisoquinolines on [3H]nitrendipine binding.

Original languageEnglish
Pages (from-to)364-379
Number of pages16
JournalCardiovascular Drug Reviews
Volume14
Issue number4
Publication statusPublished - 1996
Externally publishedYes

Fingerprint

Calcium Channel Blockers
Pharmacology
tetrandrine
L-Type Calcium Channels
Tetrahydroisoquinolines
Animal Structures
Nitrendipine
Structure-Activity Relationship
CPU 23
Antihypertensive Agents
Smooth Muscle Myocytes
Tail
Arteries
Binding Sites

Keywords

  • Antiarrhythmic
  • Antihypertensive
  • Calcium channel blocker
  • Cardiac depression
  • CPU-23
  • Vasodilatation

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Cardiovascular pharmacology of CPU-23 : A novel calcium channel blocker. / Dong, Hui; Waldron, Gareth J.; Cole, William C.; Triggle, Christopher.

In: Cardiovascular Drug Reviews, Vol. 14, No. 4, 1996, p. 364-379.

Research output: Contribution to journalArticle

Dong, Hui ; Waldron, Gareth J. ; Cole, William C. ; Triggle, Christopher. / Cardiovascular pharmacology of CPU-23 : A novel calcium channel blocker. In: Cardiovascular Drug Reviews. 1996 ; Vol. 14, No. 4. pp. 364-379.
@article{3b81094f2e1a4de3a367f2026a6b96ed,
title = "Cardiovascular pharmacology of CPU-23: A novel calcium channel blocker",
abstract = "The results of our studies conducted at the molecular, cellular, tissue, organ, and whole animals levels suggest that CPU-23 is a novel calcium channel blocker. This is further confirmed by recent studies utilizing the path-clamp technique, in which CPU-23 (1-10 μM) dose-dependently blocked inward Ca2+ currents via L-type Ca2+ channels in single smooth muscle cells isolated from the rat tail artery. Although derived from tetrandrine, CPU-23 interacts at distinct binding sites on L-type calcium channels and exerts a more potent biological action than tetrandrine. These data suggest that CPU-23, because of its novel and unique chemical structure, may be a useful tool for the study of L-type calcium channels. The obvious antihypertensive and antiarrhythmic actions of CPU-23 and its respiratory effects indicate that CPU-23 may be a useful therapeutic agent worthy of further study and development. One weakness of CPU-23 is that its potency and selectivity for the vasculature is less than those of dihydropyridine derivatives, but this may be improved by a better understanding of the structure-activity relationship of tetrahydroisoquinolines and their interaction at L-type calcium channels. This could be accomplished, for instance, by further studies of the effects of substituted tetrahydroisoquinolines on [3H]nitrendipine binding.",
keywords = "Antiarrhythmic, Antihypertensive, Calcium channel blocker, Cardiac depression, CPU-23, Vasodilatation",
author = "Hui Dong and Waldron, {Gareth J.} and Cole, {William C.} and Christopher Triggle",
year = "1996",
language = "English",
volume = "14",
pages = "364--379",
journal = "Cardiovascular Drug Reviews",
issn = "0897-5957",
publisher = "Neva Press, Inc.",
number = "4",

}

TY - JOUR

T1 - Cardiovascular pharmacology of CPU-23

T2 - A novel calcium channel blocker

AU - Dong, Hui

AU - Waldron, Gareth J.

AU - Cole, William C.

AU - Triggle, Christopher

PY - 1996

Y1 - 1996

N2 - The results of our studies conducted at the molecular, cellular, tissue, organ, and whole animals levels suggest that CPU-23 is a novel calcium channel blocker. This is further confirmed by recent studies utilizing the path-clamp technique, in which CPU-23 (1-10 μM) dose-dependently blocked inward Ca2+ currents via L-type Ca2+ channels in single smooth muscle cells isolated from the rat tail artery. Although derived from tetrandrine, CPU-23 interacts at distinct binding sites on L-type calcium channels and exerts a more potent biological action than tetrandrine. These data suggest that CPU-23, because of its novel and unique chemical structure, may be a useful tool for the study of L-type calcium channels. The obvious antihypertensive and antiarrhythmic actions of CPU-23 and its respiratory effects indicate that CPU-23 may be a useful therapeutic agent worthy of further study and development. One weakness of CPU-23 is that its potency and selectivity for the vasculature is less than those of dihydropyridine derivatives, but this may be improved by a better understanding of the structure-activity relationship of tetrahydroisoquinolines and their interaction at L-type calcium channels. This could be accomplished, for instance, by further studies of the effects of substituted tetrahydroisoquinolines on [3H]nitrendipine binding.

AB - The results of our studies conducted at the molecular, cellular, tissue, organ, and whole animals levels suggest that CPU-23 is a novel calcium channel blocker. This is further confirmed by recent studies utilizing the path-clamp technique, in which CPU-23 (1-10 μM) dose-dependently blocked inward Ca2+ currents via L-type Ca2+ channels in single smooth muscle cells isolated from the rat tail artery. Although derived from tetrandrine, CPU-23 interacts at distinct binding sites on L-type calcium channels and exerts a more potent biological action than tetrandrine. These data suggest that CPU-23, because of its novel and unique chemical structure, may be a useful tool for the study of L-type calcium channels. The obvious antihypertensive and antiarrhythmic actions of CPU-23 and its respiratory effects indicate that CPU-23 may be a useful therapeutic agent worthy of further study and development. One weakness of CPU-23 is that its potency and selectivity for the vasculature is less than those of dihydropyridine derivatives, but this may be improved by a better understanding of the structure-activity relationship of tetrahydroisoquinolines and their interaction at L-type calcium channels. This could be accomplished, for instance, by further studies of the effects of substituted tetrahydroisoquinolines on [3H]nitrendipine binding.

KW - Antiarrhythmic

KW - Antihypertensive

KW - Calcium channel blocker

KW - Cardiac depression

KW - CPU-23

KW - Vasodilatation

UR - http://www.scopus.com/inward/record.url?scp=0030430334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030430334&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 364

EP - 379

JO - Cardiovascular Drug Reviews

JF - Cardiovascular Drug Reviews

SN - 0897-5957

IS - 4

ER -